Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-year follow-up of COBRA-light versus COBRA in early rheumatoid arthritis
NL-OMON39638Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methotrexate, prednisolone and 5-aminosalicylic acid + sulphasalazine in rheumatoid arthritis (RA) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Disease activity at 48 months, Functional capacity at 48 months and 5 more. Started Apr 2013; status: active, not recruiting.
02
Drugs
methotrexateprednisolone5-aminosalicylic acid + sulphasalazine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON39638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39638.